Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 3/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12913613 | 0.83 | FFAR2 (0.30) | FFAR2 | |
| SCHEMBL22601381 | 0.76 | LIMK1 (0.40) | LIMK1ADORA2AADORA1CLK1RET | |
| SCHEMBL12946298 | 0.69 | — | — | |
| SCHEMBL10120016 | 0.68 | LIMK1 (0.37) | LIMK1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL12913603 | 0.68 | MAPK10 (0.32) | — | |
| SCHEMBL27284745 | 0.66 | ADORA2A (0.37) | LIMK1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL14005628 | 0.66 | LIMK1 (0.38) | LIMK1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL12939851 | 0.66 | — | — | |
| SCHEMBL21565922 | 0.65 | ADORA2A (0.40) | LIMK1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL23057400 | 0.65 | LIMK1 (0.38) | LIMK1ADORA2AADORA1ADORA2BPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | GALK1, PHKA1, PGK1 | LIMK1 79/4885ADORA2A 309/4885ADORA1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.